Lupin Responds To FDA Warning Letter

US Agency Criticized Novel Laboratories Facility In New Jersey

Lupin insists it has a “comprehensive remediation plan” to address deficiencies identified at its Novel Laboratories facility in New Jersey by an FDA warning letter. The Indian company says it does not anticipate any near-term commercial impact or supply disruptions linked to the letter.

Lupin logo magnifying glass
Lupin is under scrutiny from the FDA • Source: Alamy

Lupin has responded to a warning letter issued by the US Food and Drug Administration that identified a host of current good manufacturing practice deficiencies at its US Novel Laboratories facility in Somerset, New Jersey.

[Sidebar#PS144568]

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business